FDA — authorised 16 August 1949
- Application: NDA006920
- Marketing authorisation holder: LEDERLE
- Local brand name: TRIPLE SULFAS
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 SULFALOID in United States
FDA authorised SULFALOID on 16 August 1949
Marketing authorisations
FDA — authorised 23 January 1974
- Application: ANDA080079
- Marketing authorisation holder: IMPAX LABS
- Local brand name: SULFA-TRIPLE #2
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 12 June 1975
- Application: ANDA080094
- Marketing authorisation holder: PAL PAK
- Local brand name: TRIPLE SULFOID
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 August 1978
- Application: ANDA080123
- Marketing authorisation holder: LANNETT
- Local brand name: LANTRISUL
- Indication: SUSPENSION — ORAL
- Status: approved
FDA
- Application: NDA006317
- Marketing authorisation holder: LILLY
- Local brand name: NEOTRIZINE
- Indication: SUSPENSION — ORAL
- Status: approved
FDA
- Application: ANDA080013
- Marketing authorisation holder: WYETH AYERST
- Local brand name: SULFOSE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080099
- Marketing authorisation holder: FOREST PHARMS
- Local brand name: SULFALOID
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080100
- Marketing authorisation holder: FOREST PHARMS
- Local brand name: SULFALOID
- Indication: SUSPENSION — ORAL
- Status: approved
FDA
- Status: approved
SULFALOID in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is SULFALOID approved in United States?
Yes. FDA authorised it on 16 August 1949; FDA authorised it on 23 January 1974; FDA authorised it on 12 June 1975.
Who is the marketing authorisation holder for SULFALOID in United States?
LEDERLE holds the US marketing authorisation.